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Abstract
There is no consensus on optimal screening procedures for multidrug-resistant Enterobacteriaceae (MDRE) in intensive care units (ICUs).
Therefore, we assessed ﬁve strategies for the detection of extended-spectrum beta-lactamase (ESBL) and high-level expressed AmpC
cephalosporinase (HL-CASE) producers. During a 3-month period, a rectal screening swab sample was collected daily from every ICU patient,
from the ﬁrst 24 h to the last day of ICU stay. Samples were plated onMDRE-selective media. Bacteria were identiﬁed using MALDI-TOFmass
spectrometry and antibiograms were performed using disk diffusion. MDREs were isolated from 682/2348 (29.0%) screening samples collected
from 93/269 (34.6%) patients. Incidences of patients with ESBL andHL-CASE producers were 17.8 and 19.3 per 100 admissions, respectively. In
48/93 patients, MDRE carriage was intermittent. Compared with systematic screening at admission, systematic screening at discharge did not
signiﬁcantly increase the rate of MDRE detection among the 93 patients (62% vs. 70%). In contrast, screening at admission and discharge,
screening at admission and weekly thereafter, and screening at admission and weekly thereafter and at discharge signiﬁcantly increased MDRE
detection (77%, p 0.02; 76%, p 0.01; 86%, p <0.001, respectively). The difference inMDRE detection between these strategies relies essentially
on the levels of detection of patients with HL-CASE producers. The most reasonable strategy would be to collect two samples, one at
admission and one at discharge, whichwould detect 87.5% of the ESBL strains, 67.3%of theHL-CASE strains and 77.4% of all MDRE strains. This
study should facilitate decision-making concerning the most suitable screening policy for MDRE detection in a given ICU setting.
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Introduction
While third-generation cephalosporins (3GCs) are the
antimicrobial agents used most commonly for infections due
to Enterobacteriaceae, the level and spread of 3GC resistance
has become a major public health concern [1–3]. Two
dominant mechanisms contribute to 3GC resistance in
Enterobacteriaceae, the generally plasmid-mediated acquisition
of extended-spectrum b-lactamase (ESBL)-encoding genes [1]
and the high-level expression of AmpC cephalosporinase
(HL-CASE) following either in vivo selected derepression of
low-level expressed chromosome-encoded AmpC (LL-CASE)
or, less frequently, acquisition of a plasmid-borne AmpC gene
[1,4,5].
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Resistance to 3GCs is often associated with resistance to
other antibiotic families resulting in multidrug-resistant
Enterobacteriaceae (MDRE). Before the spread of
CTX-M-producing Escherichia coli, cross-contamination was
the usual pathway for acquisition of ESBL-producing
Enterobacteriaceae (ESBL strains) and hardly ever the
consequence of in vivo selected mutation [1,6]. In contrast,
in vivo selection remains the most common mode of
HL-CASE production [7,8]. In recent years, a steady increase
in the prevalence of ESBL strains has been observed in
hospitals, long-term care facilities and in the community
[9–11] while the prevalence of HL-CASE-producing Entero-
bacteriaceae (HL-CASE-strains) increased mainly in hospitals
[5,12,13].
In intensive care units (ICUs), high MDRE prevalence has
become a cause of increased morbidity and mortality, and a
major concern with respect to the most appropriate treat-
ment for infected patients [2,14–17]. Given the poor devel-
opment of new drugs active against MDRE, the ﬁght against
their cross-transmission is of major importance. A better
knowledge of the pattern of MDRE carriage in patients
admitted to ICUs would help in selecting the best screening
strategy in order to detect asymptomatic carriers, implement
prompt isolation precautions and, thereby, limit MDRE spread
[18,19]. While there is no deﬁnitive consensus on the most
effective screening strategy for the detection of asymptomatic
MDRE carriers [20], systematic screening at patient admission
has been recommended [18,19,21]. However, this strategy
does not take into account MDRE acquisition during patient
stay.
With the aim of deﬁning the most appropriate screening
strategy for detection of asymptomatic MDRE carriers in ICUs,
we performed a prospective study using systematic daily
sampling during the entire stay of ICU patients.
Methods
Settings and patients
All patients admitted to the medical and the surgical ICUs of
an 830-bed acute-care teaching hospital between 3 April and
3 July 2011 were included in the study and surveyed until
discharge. Patients already present in the ICUs on 3 April,
patients who died during the ﬁrst day of their stay and
patients who refused to participate were not included. The
study complied with conﬁdentiality regulations and ethical
standards, and, in agreement with French regulations, the
institutional review board waived the need for informed
consent (CCPPRB project number: ID-RCB 201-A00259-32,
University Paris XI, February 2011).
Screening
Using the eSwab system (Copan, Brescia, Italy), a rectal
screening swab (RSS) was collected daily from each patient
between the ﬁrst 24 h (admission RSS) and the last day in the
ICU (discharge RSS). For patients admitted late in the evening
of day 1, if no RSS was collected, the RSS collected on the next
morning (day 2) was considered the admission RSS. For
patients who died, an RSS was not systematically collected on
the last day, and the RSS of the day before was considered to
be the discharge RSS. Rectal screening results were provided
to physicians and nurses.
Microbiological tests
Each RSS was suspended in 1 mL of Liquid Amies (Copan), and
10 lL of the suspension were plated on two selective media
(ChromID, bioMerieux, Lyon, France, and Drigalski agar
ceftazidime, Becton Dickinson, Franklin Lakes, NJ, USA) using
an automated specimen-plating device (WASP; Copan, Milan,
Italy). Colonies were picked after 18 h of incubation at 37°C.
Isolates were identiﬁed using matrix-assisted laser desorption/
ionisation time-of-ﬂight mass spectrometry with a Microﬂex
Bruker Daltonics/BioTyperTM version 2.0 system (Bruker Dal-
toniks, Bremen, Germany). Antimicrobial susceptibility indica-
tive of ESBL and/or HL-CASE production was tested with the
disk diffusion method on Mueller–Hinton agar (MH; Bio-Rad,
Marnes-la-Coquette, France), according to European guidelines
[22]. An isolate was categorized as an ESBL producer when a
zone of synergy between a 3GC or aztreonam and clavulanic
acid disk was observed and as an HL-CASE producer when it
displayed (i) resistance to 3GCs, (ii) absence of synergy between
any 3GC or aztreonam and clavulanic acid, and (iii) at least a
5-mm increase in the inhibition zone diameters around the 3GC
disks, observed on MH with and without cloxacillin (250 lg/
mL). To reveal ESBL potentially masked by HL-CASE produc-
tion, synergy was tested on MH with and without cloxacillin
(250 lg/mL). All isolates categorized as ESBL and/or HL-CASE
producers were also categorized collectively as MDRE.
Imported and acquired resistant strains
When the ﬁrst RSS with an MDRE strain was collected on day
1 and/or day 2 (≤48 h), the corresponding strain was
categorized as imported; when it was collected on or after
day 3 (>48 h), the corresponding strain was categorized as
acquired (by cross-transmission or in vivo selection). In a given
patient, ESBL strains and HL-CASE strains could be imported
or acquired independently.
Cross-transmission
When two isolates belonging to the same species and with the
same antimicrobial resistance pattern were isolated from two
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patients hospitalized concomitantly in the same unit, strains
were typed using randomly ampliﬁed polymorphic DNA
analysis and the DiversiLab System (bioMerieux). Cross-trans-
mission between two patients was assumed if their stays in the
same unit overlapped for at least 1 day and if their isolates had
the same antimicrobial pattern and similar DNA ﬁngerprinting
patterns.
Screening strategies
As an RSS was collected daily from each patient, we
retrospectively and comparatively analysed the results of ﬁve
potential MDRE detection strategies: screening only at
admission (strategy A); screening only at discharge (D);
screening at admission and discharge (AD); screening at
admission and weekly thereafter (AW); screening at admis-
sion, weekly thereafter and at discharge (AWD). To
calculate the weekly detection rate of MDRE carriers, we
ﬁrst determined the number of carriers who would have
been detected, at each day of the week, if RSS had been
collected at one given day. The seven values thus obtained
were used to calculate the mean weekly detection rate.
Medical data
Demographic characteristics, severity scores at admission,
need for mechanical ventilation and mortality were recorded
for patients in the medical and surgical ICUs.
Statistical analysis
Continuous variables are presented as mean  SD and cate-
gorical variables as n (%). Comparisons between groups (ICUs)
were made using univariate analysis. For continuous variables,
the Student’s t-test was used for normally distributed variables
and theWilcoxon test for non-normally distributed variables. A
chi-square test was used for categorical variables and for
comparison of screening policies. SAS software version 9.2 (SAS
Inc., Cary, NC, USA) was used for all statistical analyses.
Results
Patients
In total, 294 patients were admitted to the two ICUs during
the study period. Small differences were observed between
the two ICU populations (Table 1) but, taking into account
that at admission carriage of ESBL strains and/or HL-CASE
strains was not statistically different between the two popu-
lations, patients were pooled in one study group for further
analysis.
The 269 patients included in the study corresponded to
2413 patient days (mean length of stay, 8.6 days; range,
2–96 days). Compliance with providing an RSS was 97.3%
(2348 RSS for 2413 patient days); compliance at admission and
discharge was 99.9% in each case.
MDRE carriers
At least one MDRE strain was isolated from 682 RSS
collected from 93 of 269 patients (34%) (Fig. 1). The
incidence of MDRE carriers (n = 93) was 34.6 per 100
admissions. The incidence of patients with an ESBL strain
(n = 48) was 17.8 per 100 admissions with a corresponding
incidence density of 19.9 per 1000 patient days, while the
incidence of patients with an HL-CASE strain (n = 52) was
19.3 per 100 admissions with a corresponding incidence
density of 21.5 per 1000 patient days.
Distribution of MDRE strains
Table 2 illustrates the distribution of the 118 MDRE strains
isolated during the study. E. coli and Klebsiella pneumoniae were
the most common ESBL producers, while Enterobacter cloacae,
E. coli and Citrobacter freundii were the most common
HL-CASE producers.
Acquired/imported cases
Figure 2 shows the results of the daily collected RSS for each
of the 93 patients with MDRE strains. Length of stay varied
from 2 to 83 days. In 61/93 patients (65.6%), the ﬁrst MDRE
strain was isolated within 48 h of admission and considered as
imported: 35 patients with only an ESBL strain, 22 patients
with only an HL-CASE strain, and four patients with an ESBL
and an HL-CASE strain. Among the four patients with an ESBL
TABLE 1. Univariate analysis comparing the patients of the
surgical and the medical intensive care units (ICUs)
Factor
Surgical
ICU
Medical
ICU
Both ICUs
pooled p-Value
Number of
patients
84 185 269 –
Age (years,
mean  SD)a
59.4 (18.7) 66.5 ( 17.7) 64.2 (18.3) 0.003b
Male sex (%) 49 (58.3) 109 (58.9) 158 (58.7) 0.93c
SAPS2
(mean  SD)
45.8 (25.8) 54.5 (23.7) 51.8 (24.7) 0.005d
Mechanical
ventilation (%)
54 (64.3) 134 (72.4) 188 (69.9) 0.18c
Death (%) 11 (13.1) 47 (25.4) 58 (21.6) 0.04c
ESBL presence at
admission (%)e
12 (14.29) 25 (13.51) 37 (13.75) 0.86c
HL-CASE presence
at admission (%)f
5 (5.95) 18 (9.73) 23 (8.55) 0.30c
MDRE presence
at admission (%)g
17 (20.24) 41 (22.16) 58 (21.56) 0.72c
aSD, standard deviation.
bParametric test.
cNon-parametric test.
dChi-squared test.
eESBL, Enterobacteriaceae harbouring extended-spectrum b-lactamase.
fHL-CASE, Enterobacteriaceae harbouring high-level expressed cephalosporinase.
gMDRE, multidrug-resistant Enterobacteriaceae (ESBL and/or HL-CASE).
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and an HL-CASE strain, patient 182 carried only an HL-CASE
strain at admission and patient 183 carried only an ESBL strain
at admission. Thus, at admission, the rate of ESBL-strain
carriage was 14.1% (38/269) while that of HL-CASE strains was
9.3% (25/269).
In 32/93 (34.4%) patients, the ﬁrst MDRE strain was
acquired during the ICU stay more than 48 h after admission
(see acquired cases, Fig. 2); that is, in six patients with only
ESBL strains, in 23 patients with only HL-CASE strains and in
three patients with both. In two patients, the ﬁrst MDRE strain
was imported, and at least one MDRE strain was acquired
(Fig. 2, patients 182 and 183). Thus, the acquired/total case
ratio was 10/48 (21%) for patients with ESBL strains (only
E. coli and K. pneumonia) and 27/52 (52%) for patients with
HL-CASE strains.
Daily sampling revealed that in 48/93 (52%) patients
MDRE-strain carriage was intermittent (Fig. 2). Intermittent
carriage concerned less often patients with ESBL (13/48, 27%)
than those with HL-CASE strains (30/52, 58%; p <0.01). In
patients with both ESBL and HL-CASE strains, these strains
were found either sequentially (patients 6 and 182) or
simultaneously (patients 185, 98, 38, 183 and 31).
Cross-transmission
Two episodes of cross-transmission with ESBL-producing
K. pneumoniae involving ﬁve patients were observed during
Eligible patients : 294
Included patients: 269
Excluded patients: 25
Early death: 21
Declining participation: 4
RSS collected: 2,348
Absence of MDRE strain(s):
Patients: 176 (65.4%)
RSS: 1,666 (71%)
Presence of MDRE strain(s):
Patients: 93 (34.5%)
RSS: 682 (29%)
Only HL-CASE strain(s):
Patients: 45 (48.4%)
RSS: 331 (48.5%)
Only ESBL strain(s):
Patients: 41 (44.1%)
RSS: 339 (49.7%)
ESBL and HLCASE strains:
Patients: 7 (7.5%)
RSS: 12 (1.8%)
FIG. 1. Flow chart describing patient
inclusion and the type of
multidrug-resistant Enterobacteriaceae
isolates (MDRE) corresponding to strains
harbouring extended-spectrum
b-lactamases (ESBL producer) and/or
high-level expressed cephalosporinase
(HL-CASE producer) isolated from 2348
rectal screening samples (RSS) from 269
patients.
TABLE 2. Distribution of the 118 multidrug-resistant Enterobacteriaceae (MDRE) strains isolated among the 93 MDRE carriers
ESBL + straina HL-CASE + strainb
No of
strains
No (%) of
strains isolated
more than 48 h
after admission
Escherichia coli ESBL + + + + 35 5 (14.3)
Klebsiella pneumoniae ESBL + + + + 16 6 (37.5)
Other species ESBL + + + + 5 0
Enterobacter cloacae HL-CASE + + + 18 12 (66.7)
Escherichia coli HL-CASE + + + + 14 5 (35.7)
Citrobacter freundii HL-CASE + + + + 10 3 (30.0)
Other species HL-CASE + + + 20 14 (70.0)
No of MDRE-patientsc 29 10 2 4 1 1 1 14 8 4 16 1 3 2 3 1
aESBL, Enterobacteriaceae harbouring extended-spectrum b-lactamase.
bHL-CASE, Enterobacteriaceae harbouring high-level over-expressed cephalosporinase.
cDistribution of patients carrying ESBL strain(s) and/or HL-CASE strain(s). Seven patients who harboured ESBL strain(s) and HL-CASE strain(s) are counted twice.
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the study (ﬁrst episode, patients 8 and 13; second episode,
patients 182, 183 and 202). No cross-transmission between
patients with HL-CASE strains was observed.
Screening strategy
When the results for all RSS collected were available, ﬁve
potential MDRE screening strategies were retrospectively
assessed. The results of these strategies are shown in Table 3.
Discussion
The results of the present study regarding the epidemiology of
MDRE colonization in ICU patients can be summarized as
follows: (i) the rate of MDRE carriage at admission is high, with
identical prevalence of ESBL and HL-CASE strains; (ii) ESBL
strains are mostly imported and HL-CASE strains mostly
acquired; (iii) carriage of MDRE is intermittent in half of the
cases; and (iv) the efﬁciency of the screening strategy varies
with the screening policy implemented.
The prevalence of ESBL-strain carriers found in this study
conducted in 2011 follows the trend observed in the last
decade. At the end of the 1990s, when the dissemination of
ESBLs was low, one report showed that only 1% of ICU
patients were colonized with an ESBL strain [20]. In the 2000s,
when CTX-M-type ESBLs emerged, an increasing prevalence of
patients with ESBL strains in ICUs, ranging from 8% in 2005 to
20% in 2010, was observed [23,24]. These studies also
Acquired cases: 32/93 MDRE carriers (34.4%)
25/32 intermittent MDRE carriers
Imported cases: 23/93 MDRE carriers (24.7%)
23 intermittent MDRE carriers
Imported cases: 38/93 MDRE carriers (40.8%)
38 continuous MDRE carriers
FIG. 2. Results obtained for daily rectal
screening samples (RSS) collected from
each of the 93 MDRE carriers with an
ESBL- and/or an HL-CASE-producing
strain during their ICU stay. The ﬁrst
column gives the sequential number
attributed to each patient included in the
study. The second column indicates the
resistance traits of the isolate(s) present in
the different RSS collected from each
patient during his/her stay: E, only ESBL
was found; C, only HL-CASE was found;
EC, ESBL and HL-CASE were found. The
other columns (day one (D1) to day 83
(D83)) show the resistance traits (E, C, E
and C strains: EC) associated with the
strain(s) isolated from RSS collected daily
from each patient during his/her entire
stay (length of stay varied from 3 to
83 days). N, RSS in which no MDRE strain
was detected; ND, no data available.
Acquired cases, ﬁrst MDRE strain
detected after 48 h of stay; imported
cases, ﬁrst MDRE strain detected within
48 h of stay; intermittent carriage,
patients in whom an RSS without an
MDRE strain was found subsequently to
an RSS with an MDRE strain.
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reported high rates of colonization with ESBL strains at
admission, ranging from 9% to 15% [23,24], similar to that
found in our study (i.e. 14.1%).
The data regarding colonization with HL-CASE strains
remain scarce. To the best of our knowledge, only one
multicentre study conducted in 2005 reported incidence rates
of MDRE colonization with ESBL and HL-CASE strains [24]. In
that study, the incidence of patients with MDRE ranged from
8.8 to 21.0/1000 patient-days and that of patients with ESBL
strains from 1.4 to 10.9/1000 patient-days, depending on the
ICU [24]. The acquired case/total case ratio was 49% for ESBL
and 60% for HL-CASE-strain carriers compared with 21% and
52%, respectively, in the present study. These results show
that a signiﬁcant proportion of patients admitted to the ICUs
were colonized with an MDRE strain (mainly ESBL) while
another signiﬁcant proportion of patients acquired an MDRE
strain under antibiotic selective pressure (mainly HL-CASE)
during the ICU stay.
The present results of daily sampling provide new informa-
tion about the variability of MDRE carriage in ICU patients.
They reveal an intermittent MDRE-strain carriage that con-
cerned 27% of patients with ESBL and 58% with HL-CASE
strains. A similar intermittent carriage was previously reported
in patients carrying methicillin-resistant Staphyloccocus aureus
[25–27]. A likely explanation for intermittent carriage of ESBL
strains might be a switch between administration and
withdrawal of different antibiotics during the ICU stay
impacting on the density of resistant strains, as shown in an
animal model [28].
With the daily collection of RSS, we investigated ﬁve
potential screening strategies (Table 3) for MDRE detection.
Overall, sampling at admission or sampling at discharge did not
show signiﬁcant differences, including ESBL and HL-CASE
carriers. Increasing the number of RSS, with one collected at
admission and one at discharge, increased the detection of
MDRE carriers signiﬁcantly, and the rate of detection was even
greater with one RSS collected at admission, one at discharge
and one weekly. The difference in detection of MDRE carriers
between these strategies is mainly due to a better detection of
patients with HL-CASE strains, in whom we found higher
acquisition and intermittent-carriage rates. Taking into account
our results and ﬁnancial considerations, the most reasonable
strategy would be to collect two samples, one at admission and
one at discharge, which would detect 87.5% of the ESBL
strains, 67.3% of the HL-CASE strains and 77.4% of all MDRE
strains.
This present work has some limitations. The study covered
a period of only 3 months and concerned only two ICUs and a
limited number of patients. Moreover, the study design was
prospective but data analysis and projections for screening
strategies were performed retrospectively. It would therefore
be interesting to compare the different strategies prospec-
tively, either simultaneously in ﬁve similar ICUs or sequentially
in one ICU. Nonetheless, to our knowledge this is the ﬁrst
report of systematic daily sampling in all patients of an ICU
from admission until discharge.
In conclusion, this study revealed high MDRE prevalence
rates in colonized patients at admission and high MDRE
TABLE 3. Evaluation of different screening strategies for the detection of the 93 multidrug-resistant Enterobacteriaceae (MDRE)
patients carrying ESBL and/or HL-CASE strains
Screening strategy
Patients with MDRE-positive screening samples
ESBL carriers a
(n = 48)
HL-CASE carriers b
(n = 52)
MDRE carriers c
(n = 93)
Nod % p Valuee No % p Value No % p Value
RSS collected
Admissionf 37 77.1 – 23 44.2 – 58 62.4 –
Discharge 38 79.2 0.805 29 55.8 0.239 66 71.0 0.213
RSS collected
Admission + discharge 42 87.5 0.181 35 67.3 0.018 72 77.4 0.025
Admission + weekly
mean valueg
40 (38–42)h 83.3 0.442 36 (34–40) 69.2 0.010 74 (69–78) 79.6 0.010
RSS collected
Admission + discharge +
weekly mean value
43 [42–44] 89.6 0.100 41 [39–45] 78.8 <0.001 80 [77–82] 86.0 <0.001
aPatients carrying Enterobacteriaceae strain(s) harbouring extended-spectrum b-lactamase (ESBL).
bPatients carrying Enterobacteriaceae strain(s) harbouring high-level over-expressed cephalosporinase (HL-CASE).
cPatients carrying ESBL and/or HL-CASE strain(s).
dNumber of patients.
EThe chi-squared test was used to compare different screening strategies with the reference policy (screening sample collected only at admission). Each strategy was considered as
statistically different from the reference policy for a p value <0.05.
fDetection of MDRE carriers at admission was chosen for reference.
gWe ﬁrst assessed the number of MDRE patients detected if sampling had been done on a deﬁned day of the week during their stay (seven values from Monday to Sunday). The
mean value was then calculated from these seven values, and values between brackets correspond to extremes of the seven values. For instance, from the 48 ESBL patients, 23
ESBL patients were detected using a systematic RSS collected on Friday and 31 ESBL patients using an RSS collected on Thursday, and the mean value for the 7 days of the week
was 27.
hExtreme values for weekly screening.
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acquisition rates during their stay. We identiﬁed a signiﬁcant
intermittent MDRE carriage, especially in patients with
HL-CASE strains. Testing different screening strategies, we
found that none was perfect because with each of them a
fraction of MDRE strains would go unidentiﬁed. Incidentally,
isolation of all patients colonised with these organisms is not
consensual, in particular of patients colonised with ESBL-pro-
ducing E. coli or derepressed AmpC-producing Enterobacter.
However, this study should facilitate decision-making concern-
ing the most suitable screening policy for the detection of
MDRE in a given ICU setting, in accordance with the local
isolation policy.
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